环磷酰胺、长春新碱、阿糖胞苷和泼尼松联合化疗（COAP）用于儿童急性淋巴细胞白血病（ALL）。
Chemotherapy with cyclophosphamide, vincristine, cytosine arabinoside, and prednisone (COAP) in childhood acute lymphoblastic leukemia (ALL).
作者信息
Sallan S E, Camitta B M, Chan D M, Traggis D, Jaffe N
出版信息
Med Pediatr Oncol. 1977;3(4):359-64. doi: 10.1002/mpo.2950030406.
Three groups of children with acute lymphoblastic leukemia (ALL) were treated with intermittent cyclophosphamide, vincristine, cytosine arabinoside, and prednisone (COAP). Group A (no prior relapse) and Group B (prior single-agent relapse) received COAP after 12 months on another chemotherapy regimen. Children in Group C (prior relapse on multiagent regimens) received COAP following A-COAP (asparaginase plus COAP) reinduction. Median disease-free survival after beginning COAP was not reached for Group A, but was only 7 months for Groups B and C. As of November 1976, there were 8 of 15 Group A patients, 1 of 12 Group B patients, and 1 of 28 Group C patients who had remained disease-free from 38 to 60 (median 54.5) months and were off chemotherapy. COAP has activity in childhood ALL. However, effectiveness is markedly diminished in patients with prior bone marrow relapse.
三组急性淋巴细胞白血病（ALL）患儿接受了间歇性环磷酰胺、长春新碱、阿糖胞苷和泼尼松（COAP）治疗。A组（既往无复发）和B组（既往单药复发）在接受另一种化疗方案12个月后接受COAP治疗。C组（既往多药方案复发）患儿在接受A-COAP（天冬酰胺酶加COAP）再诱导后接受COAP治疗。开始COAP治疗后的无病生存期，A组未达到中位数，而B组和C组仅为7个月。截至1976年11月，A组15例患者中有8例、B组12例患者中有1例、C组28例患者中有1例在停止化疗后38至60个月（中位数54.5个月）无疾病复发。COAP对儿童ALL有活性。然而，既往有骨髓复发的患者疗效明显降低。
Zotero 插件